...
首页> 外文期刊>RSC Advances >Multistage antiplasmodial activity of hydroxyethylamine compounds,in vitroandin vivoevaluations
【24h】

Multistage antiplasmodial activity of hydroxyethylamine compounds,in vitroandin vivoevaluations

机译:羟乙基胺化合物的多级抗溶液活性,vitroandin体内vivoevaluation

获取原文
获取原文并翻译 | 示例

摘要

Malaria, a global threat to the human population, remains a challenge partly due to the fast-growing drug-resistant strains ofPlasmodiumspecies. New therapeutics acting against the pathogenic asexual and sexual stages, including liver-stage malarial infection, have now attained more attention in achieving malaria eradication efforts. In this paper, two previously identified potent antiplasmodial hydroxyethylamine (HEA) compounds were investigated for their activity against the malaria parasite's multiple life stages. The compounds exhibited notable activity against the artemisinin-resistant strain ofP. falciparumblood-stage culture with 50% inhibitory concentrations (IC50) in the low micromolar range. The compounds' cytotoxicity on HEK293, HepG2 and Huh-7 cells exhibited selective killing activity with IC(50)values > 170 mu M. Thein vivoefficacy was studied in mice infected withP. bergheiNK65, which showed a significant reduction in the blood parasite load. Notably, the compounds were active against liver-stage infection, mainly compound1with an IC(50)value of 1.89 mu M. Mice infected withP. bergheisporozoites treated with compound1at 50 mg kg(-1)dose had markedly reduced liver stage infection. Moreover, both compounds prevented ookinete maturation and affected the developmental progression of gametocytes. Further, systematicin silicostudies suggested both the compounds have a high affinity towards plasmepsin II with favorable pharmacological properties. Overall, the findings demonstrated that HEA and piperidine possessing compounds have immense potential in treating malarial infection by acting as multistage inhibitors.
机译:疟疾是对人口的全球威胁,由于耐药菌株快速增长的耐药性抗药性,部分仍然是一个挑战。目前患有肝病疟疾感染的新治疗方法,包括肝脏疟疾感染,现在在实现疟疾删除努力方面更加关注。本文研究了两种先前鉴定的有效的抗溶液羟乙基胺(HEA)化合物,用于对疟疾寄生虫的多个寿命的活性。该化合物对Astemisinin抗性菌株的显着活性表现出显着的活性。恶性气球阶段培养物,具有50%抑制浓度(IC50)的低微摩拉范围。 HEK293,HEPG2和HUH-7细胞的化合物的细胞毒性表现出与IC(50)的选择性杀灭活性>在感染的小鼠中研究了蛋白体的体范素。 Bergheink65,其显示出血液寄生虫载荷的显着降低。值得注意的是,该化合物对肝阶段感染有效,主要是化合物,其IC(50)值为1.89 mu M.Mi鼠。用化合物50mg kg(-1)剂量处理的Bergheispootoites具有显着降低了肝阶段感染。此外,两种化合物都阻止了霍昔齐成熟并影响了配子细胞的发育进展。此外,Systematicin硅静脉表明,两种化合物对具有良好药理学性质的Plasmepsin II具有高亲和力。总体而言,调查结果表明,具有化合物的Hea和哌啶具有通过作为多级抑制剂来治疗疟疾感染的巨大潜力。

著录项

  • 来源
    《RSC Advances》 |2020年第58期|共15页
  • 作者单位

    Univ Delhi Hansraj Coll Univ Enclave Dept Chem Lab Translat Chem &

    Drug Discovery Delhi 110007 India;

    Loyola Univ Chicago Stritch Sch Med Dept Med 2160 South 1st Ave Maywood IL 60153 USA;

    Univ Delhi Hansraj Coll Univ Enclave Dept Chem Lab Translat Chem &

    Drug Discovery Delhi 110007 India;

    Univ Delhi Hansraj Coll Univ Enclave Dept Chem Lab Translat Chem &

    Drug Discovery Delhi 110007 India;

    South Ural State Univ Lab Computat Modelling Drugs Chelyabinsk 454080 Russia;

    South Ural State Univ Lab Computat Modelling Drugs Chelyabinsk 454080 Russia;

    Loyola Univ Chicago Stritch Sch Med Dept Med 2160 South 1st Ave Maywood IL 60153 USA;

    Natl Inst Immunol Infect Dis Lab Aruna Asaf Ali Marg New Delhi 110067 India;

    Natl Inst Immunol Infect Dis Lab Aruna Asaf Ali Marg New Delhi 110067 India;

    South Ural State Univ Lab Computat Modelling Drugs Chelyabinsk 454080 Russia;

    South Ural State Univ Lab Computat Modelling Drugs Chelyabinsk 454080 Russia;

    Pondicherry Univ Sch Life Sci Dept Microbiol Pondicherry 605014 India;

    South Ural State Univ Lab Computat Modelling Drugs Chelyabinsk 454080 Russia;

    Loyola Univ Chicago Stritch Sch Med Dept Med 2160 South 1st Ave Maywood IL 60153 USA;

    Natl Inst Immunol Infect Dis Lab Aruna Asaf Ali Marg New Delhi 110067 India;

    Univ Delhi Hansraj Coll Univ Enclave Dept Chem Lab Translat Chem &

    Drug Discovery Delhi 110007 India;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 化学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号